What’s funding like in the nuclear fusion market right now?

All funding deals in the nuclear fusion market over the last 24 months

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report covering the nuclear fusion market.

Is nuclear fusion funding actually healthier now?

Yes, nuclear fusion funding is healthier today on the things that matter most for market breadth: more deals, more funded companies, more first financings and more companies coming back for another round.

We counted 41 financings in the latest 12 months, up from 27 in the previous period. After consolidating company aliases, 30 companies raised capital versus 25 a year earlier. First financings increased from eight to 14, and there was funding activity in every monthly period we tracked.

The money itself grew much less dramatically. Quantifiable capital increased from $3.30 billion to $3.83 billion, or 16%. That figure also comes with a big caveat: only 27 of the 41 current deals disclosed a usable amount, versus 26 of 27 previously.

So we put more weight on the breadth numbers than on the headline dollars. Today, fusion has a larger active company base and a much busier funding market. At the same time, the lower end of the funding stack has not strengthened nearly as much as the top.

Metric	Current L12M	Previous 12M	Change
Deals	41	27	+51.9%
Unique companies	30	25	+20.0%
First financings	14	8	+75.0%
Companies raising more than once	8	2	+300%
Quantifiable capital	$3.83B	$3.30B	+16.2%
Median disclosed round	$73.5M	$21.2M	+246.7%
Capital below $50M	$186.4M	$241.3M	-22.8%
Months with no deal	0	2	-

Would nuclear fusion funding still look strong without the giant rounds?

Only partly. Nuclear fusion is clearly busier now, but most of the extra dollars are coming from the upper end of the market.

If we strip out every financing above $50 million, disclosed capital actually falls 23% from the previous 12 months. That is a pretty important check on the idea that funding strengthened everywhere.

The picture changes if we use a $100 million cutoff. Capital excluding rounds above $100 million increased about 22%, which means the market also built a stronger $50 million to $100 million layer. Two current disclosed rounds sit in that band, while many of the larger financings moved well beyond it.

Commonwealth Fusion Systems raised $1 billion, Proxima Fusion raised $468 million, Helion initially closed $465 million in its Series G, and Inertia announced a $450 million milestone-based financing. Those rounds did a lot of work in the headline total.

The cleaner reading is that the fusion funding ladder moved upward. Small and sub-$50 million disclosed funding did not improve, while the market became much better at financing companies once they reached larger scale.

Are just a few nuclear fusion companies still taking all the money?

Large nuclear fusion rounds still absorb most of the money, but the top of the market is less concentrated than it was a year ago.

The three biggest deals accounted for about half of current disclosed capital, compared with two-thirds in the previous period. The top five fell from 78% to 68% of capital. That is a meaningful change for a sector where a single financing can completely distort a yearly total.

What has broadened is the group capable of raising nine-figure checks. CFS, Proxima, Helion, Inertia, Focused Energy, Thea Energy, Startorus, NovaFusion and Xinghe Fusion all raised or announced large financings during the current period. A wider group raising nine-figure checks is one growth driver we follow when we ask what fusion needs to speed up in our market report about nuclear fusion.

At the same time, 86% of disclosed dollars still came from rounds above $100 million. Fusion remains a market where a relatively small number of technically advanced companies consume enormous amounts of capital.

The improvement is in the number of large winners, rather than any real disappearance of concentration.

Concentration measure	Current	Previous
Largest deal / disclosed capital	26.1%	27.3%
Top 3 / disclosed capital	50.4%	66.4%
Top 5 / disclosed capital	68.4%	78.2%
Top 10 / disclosed capital	86.1%	92.7%
Deals above $50M	14	10
Deals above $100M	10	7
Capital from deals above $50M	95.1%	92.7%
Capital from deals above $100M	86.1%	86.7%

Are more nuclear fusion startups actually getting funded now?

Yes. Nuclear fusion funding is reaching more companies now, and we are also seeing more genuinely new funded startups.

The number of funded companies rose from 25 to 30 after we normalized different names used for the same businesses. More importantly, first financings jumped from eight to 14.

That new cohort is quite varied. Inertia came out with an unusually large $450 million milestone-based Series A. Xinghe Fusion raised roughly $122 million. Starlight Engine raised $37.4 million. Fusionality and Daedal Systems entered through much smaller control-and-diagnostics rounds. Several newly funded Chinese companies, including Beta Fusion and UniFusion, disclosed only broad RMB ranges rather than precise amounts.

Existing companies were busier too. Eight businesses raised more than once during the latest period, versus only two previously.

As seen above, deal count grew much faster than the number of companies. The current expansion combines new-company creation with much more repeat fundraising.

Are investors backing new nuclear fusion companies or mostly doubling down on winners?

Investors are doing both, but most of the money now goes into nuclear fusion companies that have already raised before.

First financings became more common, rising from 29.6% to 34.1% of deals. The median disclosed first round stayed fairly stable at $21 million versus $24 million previously, which suggests the market has not suddenly made it dramatically more expensive to create a new funded fusion company.

Follow-ons changed much more. Quantifiable follow-on capital rose from about $2.05 billion to $3.21 billion, while the median disclosed follow-on round increased from $18.4 million to $73.9 million.

That is where the financing ceiling has really moved.

CFS, Proxima, Helion and Startorus all came back for substantial additional capital. NovaFusion also raised repeatedly within a very short period after its creation. Investors are still opening the door to new teams, but once a company shows enough technical and organizational progress, the amount of capital available to it can now become much larger.

Financing type	Current	Previous
First-financing deals	14	8
First-financing share	34.1%	29.6%
Disclosed first-financing capital	$621.8M	$1.251B
Median disclosed first financing	$21.0M	$24.0M
Follow-on deals	27	19
Follow-on share	65.9%	70.4%
Disclosed follow-on capital	$3.211B	$2.047B
Median disclosed follow-on	$73.9M	$18.4M

Are nuclear fusion startups raising again faster now?

Nuclear fusion companies are clearly returning to investors more often within the year, although we cannot calculate a reliable market-wide time between rounds.

The clearest evidence is the jump in companies completing multiple financings inside the same 12-month window. That number rose from two to eight, taking the repeat-fundraising rate from 8% to 26.7%.

Startorus announced several financings during 2026. Dongsheng Fusion, also reported as SunUp Fusion, moved through multiple rounds in quick succession. NovaFusion followed its first large financing with additional capital within months. Helion expanded its Series G after the initial close.

We stop short of saying the average funding interval has fallen by a specific number of months. Our database does not contain a complete structured previous-round history for every company, and reconstructing it from partial public records would create false precision.

Still, the behavior inside the current period is hard to miss: a larger group of fusion companies can now come back to the market repeatedly and keep getting funded.

Why are nuclear fusion companies getting so much younger?

Nuclear fusion funding has shifted sharply toward younger companies, especially because of a new generation of Chinese startups that is raising very quickly after formation.

The median age of a funded company fell from 4.4 years to 1.8 years. The average dropped from 7.4 to 3.9 years. A funded cohort this young carries risks we rate by likelihood, including the less obvious ones, in our report on nuclear fusion.

The change is bigger than what we see in first rounds alone. The median company age at first financing barely moved, from about 1.46 years to 1.25 years. What changed more is the age of companies raising follow-ons.

Dongsheng Fusion was founded in 2025 and had already completed several financings by 2026. NovaFusion was also founded in 2025 and moved through multiple large rounds rapidly. BlueStar Fusion, SuperMag Energy, Beta Fusion and Xinghe Fusion belong to the same recent wave.

So the fusion market is producing more young startups, but that is only part of it. Some are moving through fundraising cycles unusually fast, which pulls the age of the whole funded cohort down.

Is China taking over nuclear fusion funding?

China is currently dominating nuclear fusion deal formation, but North America still dominates the largest disclosed dollar flows.

Chinese companies completed 24 financings in the latest period, up from only four. China now represents 58.5% of all deals in our dataset, compared with 14.8% a year earlier.

The companies are also raising meaningful amounts. Startorus announced several large rounds. NovaFusion raised roughly $102.5 million in one financing and later announced a $178.6 million Pre-A financing series. Xinghe Fusion raised around $122 million. The median disclosed Chinese deal reached about $101 million, up from roughly $69 million previously.

North America followed a completely different path. Deal count stayed flat at eight, yet the region still accounted for 54% of disclosed capital thanks largely to CFS, Helion and Inertia.

Europe had fewer deals but bigger checks, helped by Proxima's $468 million financing and Focused Energy's $240 million round.

These days, China is where most of the new funding activity is being created, while the United States still has exceptional depth when a fusion company needs several hundred million dollars or more.

Geography	Current deals	Previous deals	Current capital share	Previous capital share
China	24	4	25.0%	9.8%
Asia-Pacific overall	29	12	26.8%	12.1%
North America	8	8	53.7%	77.2%
Europe	4	7	19.4%	10.7%
China deal share	58.5%	14.8%	-	-
APAC median disclosed round	$73.5M	$12.3M	-	-
North America median	$67.5M	$140.0M	-	-
Europe median	$136.9M	$33.2M	-	-

Which nuclear fusion technology is investors' favorite right now?

Tokamaks currently have the broadest funding momentum, while stellarators and inertial fusion are attracting much larger checks than they did a year earlier.

Tokamak deals tripled from four to 12 and their share of the market rose from 14.8% to 29.3%. Startorus was one of the busiest fundraisers. Dongsheng/SunUp emerged as another fast-moving company, while Starlight Engine joined the market with a $37.4 million first financing.

Stellarators gained less in deal count but much more in dollars. Their capital share rose from 6.5% to 19.3%, helped by Proxima's $468 million round and Thea Energy's $100 million Series B.

Inertial fusion is an even clearer example of money moving faster than deal volume. Its deal share slipped slightly, yet its capital share jumped from 2.7% to 19%. Inertia's $450 million financing and Focused Energy's $240 million round drove most of that change.

Alternative-confinement approaches went the other way: five deals versus nine previously. Some individual companies still raised significant amounts, particularly NovaFusion, but fewer businesses in the category received financing.

Fusion approach	Current deals	Previous deals	Current capital share	Previous capital share
Tokamak	12	4	39.0%	35.7%
Stellarator	7	4	19.3%	6.5%
Inertial fusion	5	4	19.0%	2.7%
Alternative confinement	5	9	7.5%	9.7%
Pulsed / magneto-inertial	7	4	15.0%	44.7%
Controls & diagnostics	3	0	0.2%	-
Magnet & power systems	2	0	Undisclosed	-

Is nuclear fusion becoming an earlier-stage market?

Nuclear fusion is becoming earlier-stage by deal count, while the dollar mix is much harder to classify cleanly.

Early-stage financings increased from 59.3% to 68.3% of deals. Later-stage financings fell from 22.2% to 9.8%.

But almost half of current disclosed capital sits in rounds where no conventional stage was publicly established. That group includes CFS's $1 billion financing and Proxima's $468 million round. Rounds with no stage label are hard to read, so we cover what investors back and avoid in our report on nuclear fusion.

This is increasingly common in fusion. Once companies move beyond normal venture-company development and start financing huge engineering programs, industrial facilities or first-of-a-kind plants, Series labels become less informative. Some transactions are simply announced as equity rounds.

So we are comfortable saying that more early companies are being financed now. We are much less comfortable saying the money itself has shifted to early stage. A large chunk of current capital is going into advanced programs whose financing labels no longer fit neatly into Seed, Series A, B or later-stage buckets.

Are nuclear fusion investors getting pickier?

Nuclear fusion investors look more selective around large strategic checks, even though the total number of disclosed investors has barely changed.

We identified 55 unique disclosed investors in the current period versus 54 previously, while deal count increased by more than half. Current investor disclosure is also worse, so we would not push that comparison too far.

Strategic participation gives us a clearer picture. Corporate or strategic investors appeared in 29.3% of deals, down from 55.6%. Yet the median disclosed round involving strategic capital rose from $18.4 million to $55.5 million.

RWE backed major European financings involving Proxima and Focused Energy. Google joined Proxima's large round. Hyundai invested as part of CFS's $1 billion fundraise and is exploring collaboration around future ARC plants. Helion's Series G brought in another set of institutional investors as the company expanded manufacturing.

Corporate capital therefore looks less evenly spread these days. It is showing up around bigger projects where the company can point to a specific plant, industrial system, commercial partnership or deployment plan.

Do nuclear fusion startups need more proof before investors write a huge check?

Yes. The biggest nuclear fusion rounds today are increasingly tied to concrete engineering and commercialization plans rather than a promising scientific idea alone.

CFS raised $1 billion while building SPARC and preparing the transition toward commercial ARC power plants. Proxima's €411 million financing is funding its Alpha stellarator project, more hiring and deeper vertical integration. Helion said its latest round would expand U.S. manufacturing capacity and accelerate commercial deployment.

Inertia offers an especially revealing example. Its $450 million Series A is milestone-based, meaning the headline commitment is linked to the company's progress rather than being completely available from day one.

Government policy is also moving in the same direction. The U.S. Department of Energy's 2026 Fusion Science and Technology Roadmap organizes public-private work around measurable technical gaps, pilot plants, supply chains and commercialization. The UK government's 2026 fusion strategy is similarly focused on turning research strength into industrial capacity and deployment.

Early fusion startups can still raise on technical potential. The several-hundred-million-dollar checks now require a much more credible path from experiment to engineered system.

Is nuclear fusion finally moving from science projects to an industry?

Nuclear fusion is currently moving into an industrial build-out phase, even though nobody can yet say that commercial fusion power has been solved.

The use of large rounds has changed noticeably. Helion is spending on manufacturing and deployment. Proxima is funding hardware execution and vertical integration. CFS is preparing for ARC power plants while SPARC advances. Kyoto Fusioneering has been raising equity alongside project financing to scale engineering work around systems such as UNITY and FAST. Firms scaling toward power plants raise the question of which business models make money, which we compare in our report covering the nuclear fusion market.

The latest supply-chain data backs this up. In its 2026 survey, the Fusion Industry Association found that reported fusion supply-chain spending increased 24% during 2025. Among the suppliers surveyed, 75% had invested in additional fusion capacity, with individual investments ranging from $30,000 to $65 million. Participating fusion companies expected their supply-chain spending to rise another 27% in 2026.

The U.S. and UK governments are now explicitly talking about fusion in terms of supply chains, manufacturing capacity, systems integration, planning and future deployment.

We still do not know which reactor concepts will work economically at scale. But the financing market is already paying for much more than plasma physics.

Are companies building picks and shovels for nuclear fusion now?

Yes. A small but noticeable group of nuclear fusion startups is now raising money specifically for the tools, controls and hardware that reactor developers will need.

Three current deals in our dataset sit in fusion controls and diagnostics, while another two focus on magnet and power systems. Neither category appeared in the previous comparison period.

Fusionality, founded by former Google DeepMind researchers, raised $3.7 million for software and control tools designed to speed up fusion development. Daedal Systems raised just over $4 million. VeloAlpha also entered through the diagnostics and controls layer. SuperMag is targeting the magnet and power-system side of the ecosystem.

These are still tiny categories compared with reactor companies, so it would be premature to call this a major funding segment.

The direction is worth watching, though. The Fusion Industry Association's latest supplier survey found growing investment in fusion capacity alongside persistent bottlenecks in materials, heat management and fuel systems. The UK's current fusion strategy also places supply-chain development at the center of commercialization.

An ecosystem that once mainly financed reactor concepts is now beginning to finance the companies around them.

Is the huge jump in the median nuclear fusion round believable?

The nuclear fusion median clearly moved upward, but the reported jump from $21.2 million to $73.5 million makes the change look more precise than the underlying disclosure allows.

Fourteen of the 41 current financings have no usable exact amount. Only one deal had that problem in the previous period.

A large share of those missing amounts comes from Chinese financings announced only as "tens of millions" or "hundreds of millions" of RMB. We deliberately did not turn those descriptions into invented dollar estimates.

What we can verify more confidently is what happened at the top. The number of disclosed $100 million-plus rounds rose from seven to 10. Follow-on round sizes also moved sharply upward, as discussed earlier.

That makes the direction convincing: large fusion checks have become more common. The exact 247% increase in the median should be treated as a rough measure of that shift rather than a precise statement about the typical deal.

What would people get wrong by looking only at nuclear fusion's total funding?

The biggest mistake would be to see nuclear fusion funding up 16% and conclude that every part of the market improved by roughly the same amount.

The underlying change is much more dramatic than the headline total suggests.

Deal activity expanded quickly, new-company formation picked up, repeat fundraising became common, China produced an extraordinary number of new financings, and several technologies developed a much deeper large-round market. At the same time, disclosed sub-$50 million capital shrank and current deal-size disclosure is much worse. Seeing which companies sit behind each region's financings is what the market maps and grids in our report on nuclear fusion are for.

The current market has effectively stretched in both directions. More young companies are getting funded at the bottom, while proven companies can raise several hundred million dollars at the top. The middle and lower funding layers did not strengthen at the same pace.

That is why we see nuclear fusion today as a healthier and more mature financing market, but still an uneven one. The industry has more breadth and more ability to finance scale, while remaining heavily dependent on a relatively small group of capital-intensive winners.

What really changed over the last 12 months?

Nuclear fusion funding is healthier today because the active market is broader. We found more deals, more funded companies, more first financings and far more companies raising repeatedly.

The biggest financial change happened after companies had already proven enough to come back for another round. Follow-on checks became much larger, with several companies now able to access hundreds of millions of dollars.

China created most of the new deal breadth. North America, however, remains the deepest market for the very largest disclosed financings.

Technology momentum also split in different directions. Tokamaks added the most breadth, stellarators attracted much more capital, and inertial fusion produced several exceptionally large financings. Alternative confinement had fewer funded companies.

Investors are increasingly financing engineering execution, manufacturing, supply chains and future deployment. Recent company announcements and the latest U.S., UK and industry reports all point in that direction.

The misleading headline is the 16% increase in disclosed funding. The more important story is that fusion now has a larger startup pipeline and a much stronger scale-up financing market at the same time, even though funding below the large-round tier remains comparatively weak.